辽宁成大生物股份有限公司 2024年持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司持续督导工作指引》等有关法律、法规的规 定，中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为正在对辽宁 成大生物股份有限公司（以下简称"成大生物"、"上市公司"、"公司"）进行持续 督导工作的保荐人，对公司2024年度持续督导期间（以下简称"本持续督导期"） 的规范运行情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 中信证券股份有限公司关于 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 洪立斌、赵洞天 （三）现场检查时间 2025年4月15日至2025年4月30日 （四）现场检查人员 赵洞天、杜博闻 （五）现场检查内容 （一）公司治理和内部控制情况 现场检查人员查阅了上市公司最新章程、三会议事规则及会议材料，财务管 理、内部审计、募集资金管理、对外担保管理制度、关联交易制度等相关内控制 度，查阅了公司 2024 年度内部控制自我评价报告、2024 年度内部控制审计报告 等文件。 经查阅前述文件，保 ...

一、发行人基本情况 注：成大生物控股股东辽宁成大股份有限公司（"辽宁成大"）于 2025 年 2 月 28 日完成控 制权变更，成大生物间接控股股东由辽宁国资经营公司变更为韶关高腾，实际控制人由辽宁 省国资委变更为无实际控制人。 二、本次发行情况概述 根据中国证券监督管理委员会于 2021 年 9 月 14 日出具的《关于同意辽宁成 大生物股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3019 号），公司首次公开发行人民币普通股（A）股 41,650,000.00 股，每股发行价格 为 110.00 元，募集资金总额为人民币 4,581,500,000.00 元；扣除发行费用 240,120,566.26 元，实际募集资金净额为人民币 4,341,379,433.74 元。上述募集资 1 中信证券股份有限公司关于 辽宁成大生物股份有限公司 首次公开发行股票并在科创板上市 持续督导保荐总结报告书 保荐人编号：Z20374000 申报时间：2025 年 5 月 | 公司名称 | 辽宁成大生物股份有限公司 | | --- | --- | | 英文名称 | Liaoning Chengda Biote ...

中信证券股份有限公司 建议公司继续严格按照《公司法》《证券法》《上海证券交易所股票上市规 则》等法律法规的要求，不断完善公司治理结构，持续加强内部控制建设，及时 履行信息披露义务，合规合理使用募集资金，有序推进募投项目的建设及实施， 确保募投项目完成并实现预期收益。 附件：中信证券股份有限公司关于辽宁成大生物股份有限公司2024年持续督 导工作现场检查报告 （以下无正文） (本页无正文,为《中信证券股份有限公司关于辽宁成大生物股份有限公司 2024 年持续督导工作现场检查结果及提请公司注意事项》之盖章页） 关于辽宁成大生物股份有限公司 2024年持续督导工作现场检查结果及提请公司注意事项 辽宁成大生物股份有限公司： 中信证券股份有限公司（以下简称"本保荐人"）作为对贵公司进行持续督导 的保荐人，按照《上海证券交易所上市公司自律监管指引第11号——持续督导》 的有关要求，对贵公司认真履行了持续督导职责。 基于2024年度现场检查，本保荐人提请贵公司关注以下事项： ...

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]

辽宁成大生物股份有限公司 2024 年年度股东大会会议资料 证券代码：688739 证券简称：成大生物 辽宁成大生物股份有限公司 2024 年年度股东大会 会议资料 辽宁成大生物股份有限公司 Liaoning Chengda Biotechnology Co., Ltd. 二〇二五年五月十四日 中 国·沈 阳 1 辽宁成大生物股份有限公司 2024 年年度股东大会会议资料 目录 辽宁成大生物股份有限公司 2024 年年度股东大会会议资料 | 2024 年年度股东大会会议须知 | | | 3 | | | --- | --- | --- | --- | --- | | 2024 年年度股东大会会议议程 | | | 5 | | | 2024 年年度股东大会会议议案 | | 7 | | | | 议案一：关于公司《2024 | | 年度董事会工作报告》的议案 7 | | | | 议案二：关于公司《2024 | | 年度监事会工作报告》的议案 16 | | | | 议案三：关于公司《2024 | | 年年度报告及摘要》的议案 21 | | | | 议案四：关于公司《2024 | | 年年度财务决算报告》的议案 22 | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 □适用 √ ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 358,395,731.16, a decrease of 1.73% compared to CNY 364,709,258.37 in the same period last year[5] - Net profit attributable to shareholders was CNY 72,218,005.25, down 11.35% from CNY 81,463,701.09 year-on-year[5] - Total revenue for Q1 2025 was CNY 358,395,731.16, a decrease of 1.1% compared to CNY 364,709,258.37 in Q1 2024[19] - Net profit for Q1 2025 was CNY 72,218,005.25, down 11.3% from CNY 81,463,701.09 in Q1 2024[19] - Operating profit for Q1 2025 was ¥88,612,647.35, down 48.6% from ¥172,340,409.52 in Q1 2024[29] - Net profit for Q1 2025 was ¥80,196,541.41, a decline of 45.0% compared to ¥145,908,490.99 in Q1 2024[29] Cash Flow - The net cash flow from operating activities increased by 15.77% to CNY 38,495,548.95, compared to CNY 33,252,685.73 in the previous year[5] - Cash flow from operating activities for Q1 2025 is ¥38,495,548.95, an increase of 15.5% compared to ¥33,252,685.73 in Q1 2024[22] - The net cash flow from operating activities for Q1 2025 was ¥25,693,550.62, down 67.2% from ¥78,399,476.34 in Q1 2024[31] - The company reported a cash inflow from sales of goods and services of ¥306,402,043.44 in Q1 2025, down 13.4% from ¥353,763,410.47 in Q1 2024[22] - The net cash flow from investment activities is -¥573,711,775.49, a significant decrease from ¥27,185,195.69 in the previous period[23] - The company reported a net cash outflow from investing activities of ¥528,225,792.41 in Q1 2025, compared to a smaller outflow of ¥50,151,806.51 in Q1 2024[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,080,623,416.18, reflecting a slight increase of 0.29% from CNY 10,051,587,266.31 at the end of the previous year[6] - Total assets as of March 31, 2025, were CNY 10,080,623,416.18, slightly up from CNY 10,051,587,266.31 at the end of 2024[17] - Total liabilities decreased to CNY 445,937,459.82 from CNY 489,119,315.20, a reduction of 8.8%[17] - Total liabilities decreased to ¥328,712,007.83 from ¥364,821,816.98, indicating a reduction of 9.9%[27] - The company’s total equity increased to CNY 9,634,685,956.36 from CNY 9,562,467,951.11, reflecting a growth of 0.8%[17] - The total equity increased to ¥10,062,485,088.05 from ¥9,982,288,546.64, reflecting a growth of 0.8%[27] Research and Development - Research and development expenses totaled CNY 86,826,788.11, representing 24.23% of operating revenue, a decrease of 1.92 percentage points from 26.15%[6] - Research and development expenses for Q1 2025 were CNY 51,861,758.56, down 12.1% from CNY 58,997,464.13 in Q1 2024[19] - Research and development expenses increased significantly to ¥63,157,263.29 in Q1 2025, compared to ¥19,874,594.47 in Q1 2024, reflecting a growth of 217.5%[29] Shareholder Information - The company reported a total of 25,451 common shareholders at the end of the reporting period[9] - The controlling shareholder, Liaoning Chengda, holds 54.67% of the company's shares, with a change in control from a state-owned entity to a private management company[11] - The company has completed the legal procedures for a mandatory general offer to all shareholders due to the change in control[11] Earnings Per Share - The basic and diluted earnings per share were both CNY 0.18, a decrease of 10% from CNY 0.20 in the same period last year[5] - Basic and diluted earnings per share for the current period are both ¥0.18, down from ¥0.20 in the previous period, reflecting a 10% decline[20] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 3,961,121,082.99 from CNY 4,496,464,173.92 as of December 31, 2024, a decline of 11.9%[15] - Cash and cash equivalents at the end of the period are ¥3,962,685,051.08, down from ¥4,587,507,490.87 in the previous year, indicating a decrease of 13.6%[23] - The beginning balance of cash and cash equivalents was 4,421,617,178.42, while the ending balance was 3,918,934,767.46[32] Accounting Standards - The company will first implement new accounting standards starting from 2025, which will affect the financial statements[32]

成大生物公告，2025年第一季度营收为3.58亿元，同比下降1.73%；净利润为7221.8万元，同比下降 11.35%。 ...

Group 1 - The State Council Information Office will hold a press conference on April 28 to discuss policies related to stabilizing employment and the economy, promoting high-quality development [1] - The National Development and Reform Commission, Ministry of Human Resources and Social Security, Ministry of Commerce, and the People's Bank of China will present relevant measures and answer questions [1] Group 2 - The China Council for the Promotion of International Trade will hold a press conference on April 28 to release the global trade friction index for February 2025 and other trade-related data [3] - The press conference will also cover the latest preparations for the third Chain Expo and new policies to support foreign trade [3] Group 3 - The China Meteorological Administration will hold a press conference on April 28 to discuss the national weather and climate characteristics for April, as well as predictions for May [4] Group 4 - The first "Beijing Xiangshan Forum" will take place from April 28 to 30, focusing on global security challenges and opportunities, with participation from over 200 defense officials and experts from more than 30 countries [5] Group 5 - On April 28, a total of 17 companies will have their restricted shares released, amounting to 1.727 billion shares with a total market value of 24.677 billion yuan [6] - Companies with the highest share unlock volumes include China Resources Materials, Chengda Bio, and Wangbian Electric [6] Group 6 - 19 companies announced stock repurchase progress on April 28, with 18 companies disclosing new repurchase plans [7] - The highest repurchase amounts were reported by Tianyuan Environmental Protection, Jinli Permanent Magnet, and Zhenhua Heavy Industry [7] Group 7 - A total of 176 billion yuan in 7-day reverse repos will mature today, with an operation rate of 1.5% [8]

智通财经APP获悉，4月28日共有27家上市公司的限售股解禁，解禁总市值约317亿元。 今日具体限售解禁股情况如下： | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 时代新材 | 600458 | 股权激励限售流通 | 649.44万 | | 中航沈飞 | 600760 | 股权激励限售流通 | 361.77万 | | 中钢天源 | 002057 | 股权激励限售流通 | 424.38万 | | 万讯自控 | 300112 | 股权激励限售流通 | 171.15万 | | 新研股份 | 300159 | 股权激励限售流通 | 540万 | | 吉鑫科技 | 601218 | 股权激励限售流通 | 54.63万 | | 凯龙股份 | 002783 | 股权激励限售流通 | 9.74万 | | 东方精工 | 002611 | 股权激励限售流通 | 88万 | | 星帅尔 | 002860 | 股权激励限售流通 | 30.2万 | | 星光农机 | 603789 | 股权激励限售流通 | 513.57万 | | 口子窖 | 603589 | 股权 ...